Lundbeck Begins Phase I Trials for Neurological Disease Candidate

Lundbeck has started Phase I trials to investigate the safety, tolerability and pharmacokinetic profile of Lu AA47070 in humans.

Lu AA47070 is a novel adenosine receptor antagonist shown to be efficacious in animal models for neurological diseases, including Parkinson’s.

Peter Høngaard Andersen, Lundbeck’s head of research, said Lu AA47070 is the company’s first internal compound in the neurology area.